On May 7th, the reporter learned from Xuanwu Hospital of Capital Medical University that a study conducted by Professor Ji Xunming's team showed that intravenous use of tirofiban for antiplatelet therapy within 24 hours of onset in patients with acute ischemic stroke can significantly reduce early neurological deterioration. The relevant results were recently published in the Journal of the American Medical Association Neurology. The deterioration of neurological function in acute ischemic stroke is closely related to adverse clinical outcomes. Oral antiplatelet therapy regimens such as aspirin have been proven to reduce stroke recurrence rates and improve clinical outcomes. However, due to drug resistance, slow onset time, and swallowing disorders in some patients, using current antiplatelet regimens such as oral aspirin to treat acute ischemic stroke still results in 10% to 20% of patients experiencing neurological deterioration. Tirofiban is an intravenous antiplatelet drug that can be used. To clarify the role of intravenous application of tirofiban in reducing early neurological deterioration in acute ischemic stroke, the research team initiated a multicenter, open label, randomized controlled study. The team enrolled 425 patients with acute non cardiogenic ischemic stroke who did not receive intravenous thrombolysis or thrombectomy in 10 centers in China. Within 24 hours of stroke onset, 213 patients were randomly given intravenous tirofiban or oral aspirin alone (212 patients). The results showed that the incidence of neurological deterioration within 72 hours in patients treated with intravenous tirofiban was only 4.2%, while the incidence of neurological deterioration within 72 hours in patients treated with conventional oral antiplatelet drugs was 13.2%. Meanwhile, there was no significant difference in the symptomatic intracerebral hemorrhage rate between the two groups of patients within 72 hours. Tudor Gavin, President of the American Stroke Conference, commented that the research findings provide a promising treatment option for ischemic stroke patients who have missed intravenous thrombolysis or mechanical thrombectomy. Lauren Sansing, Director of the Stroke and Vascular Neurology Department at Yale University School of Medicine, believes that the research findings provide a new antiplatelet treatment option for patients with ischemic stroke, in addition to aspirin. (Lai Xin She)